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Abstract
Background: A possible role of vitamin D in depression has received considerable attention, especially given the significant disability, mortality, 
and healthcare costs associated to depression and the high prevalence of vitamin D deficiency.
Methods: We investigated the cross-sectional associations between serum 25-hydroxyvitamin D (25OHD) levels and depressive symptoms 
(CES-D) in 5,607 older adults from the English Longitudinal Study of Ageing (ELSA).
Results: Overall, there was a significant association between low 25OHD levels and elevated depressive symptoms (odds ratio [OR] = 1.58, 
95% confidence interval [CI] = 1.20–2.07 for the lowest quartile; OR = 1.45, 95% CI = 1.15–1.83 for <30 nmol/L cut-off and OR = 1.34, 
95% CI = 1.10–1.62 for the ≤50 nmol/L cut-off) after adjustment for a wide range of covariates of clinical significance. Fully adjusted models 
showed that women in the lowest (OR = 1.67, 95% CI = 1.20–2.34) and second lowest (OR = 1.68, 95% CI = 1.20–2.35) quartiles of 25OHD 
as well as those with 25OHD levels <30 nmol/L (OR = 1.40, 95% CI = 1.06–1.86) and ≤50 nmol/L (OR = 1.35, 95% CI = 1.07–1.72) were 
more likely to report elevated depressive symptoms. For men, however, this association only remained significant for those with 25OHD levels 
of <30 nmol/L (OR = 1.60, 95% CI = 1.06–2.42) in the fully adjusted models.
Conclusions: The independent and inverse association found between low 25OHD levels and elevated depressive symptoms suggests that 
vitamin D deficiency may be a risk factor for late-life depression, particularly among women. Whether our findings have any clinical meaning 
or not, additional data are needed from well-designed randomized controlled trials of vitamin D for the prevention and treatment of late-life 
depression.
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Depression is associated with significant disability, mortality, and 
high healthcare costs (1). It is responsible for between 5% and 
8% of the total disability-adjusted life years (DALYs) in middle 
and high-income countries (2). Despite its high prevalence, how-
ever, depression among older adults tends to be under-recognized 
and under-treated (3). Although the underlying pathophysiology of 
depression remains unknown, recent advances in basic and clinical 
research highlighted the potential role of new biological factors that 
may affect mood in combination with the more traditional neuro-
chemical and neuroendocrine mechanisms (4).
Low vitamin D status is a major public health problem world-
wide, particularly in older people (5). It is projected that about 1 
billion people globally have vitamin D deficiency or insufficiency (6). 
The serum concentrations of 25-hydroxyvitamin D (25OHD), the 
major storage and circulating form of vitamin D rises and falls with 
the supply of vitamin D3 (cholecalciferol) and vitamin D2 (ergocal-
ciferol). Older adults are at increased risk of poor vitamin D status 
due to the lack of sun exposure and to an age-related decline in the 
efficiency of vitamin D synthesis and metabolism (7). The impor-
tance of vitamin D in the absorption and metabolism of calcium 
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for bone health is well established (8). Besides its effect on calcium 
metabolism and bone health, vitamin D deficiency has been linked to 
various diseases and proposed to be a universal risk factor for mul-
tiple multifactorial diseases. For example, studies demonstrated that 
low 25OHD concentrations may promote the pathogenesis of type 1 
diabetes (9), rheumatoid arthritis (10), multiple sclerosis (11), sarco-
penia (12), cancer (13), and other diseases. Other actions of vitamin 
D include its impact on the innate and adaptive immunity (14).
A possible role of vitamin D in depression has received con-
siderable attention. To date epidemiological evidence from several 
cross-sectional studies have shown an association of vitamin D defi-
ciency with an increase in depression (15). Very few longitudinal 
studies, with conflicting findings, have prospectively explored the 
relationship between vitamin D deficiency and late-life depression 
(16,17). Evidence from recently published systematic reviews and 
meta-analyses (15,18–20) identified an overall significant associa-
tion between depression and vitamin D deficiency. However, non-
significant findings from another meta-analysis have been reported 
(21). Furthermore, causality and efficacy of supplementation remain 
controversial.
Given the high prevalence of both vitamin D deficiency and 
depression, an association between these two conditions would have 
significant public health and clinical implications. The evidence for 
older adults from the general population in England is scarce and 
outdated. Therefore, the primary objective of this cross-sectional 
analysis was to investigate the association between the 25OHD 
concentrations and depressive symptoms, using data from the 
English Longitudinal Study of Ageing (ELSA). ELSA was designed 
to be nationally representative of community dwelling adults aged 
50 years and older from the general population of England, United 
Kingdom.
Methods
Study Population
ELSA is an ongoing prospective observational study of community-
dwelling people aged 50 years and over in England that commenced 
in 2002. The ELSA sample was drawn from participants that had 
previously participated in the Health Survey for England (HSE); an 
annual health examination survey, which each year recruits a differ-
ent nationally representative sample using a multi-staged stratified 
random probability design (22). After baseline, follow-up interviews 
within ELSA occur every 2 years and health examinations, that is, a 
nurse visit, every 4 years. The first health examination was in 2004–
2005. A detailed description of the study can be found elsewhere 
(23). Analyses for this study used cross-sectional data from wave 6 
(2012–2013) as this was the first time that 25OHD concentrations 
were ascertained in ELSA.
Assessment of 25OHD
Wave 6 had 10,601 respondents that also included noncore mem-
bers, such as, partners. Only the 9,169 core sample members eli-
gible for a nurse visit at which blood samples could be taken were 
included. Of those, 7,730 had a nurse visit. Blood samples were 
obtained from 6,206 participants, and 25OHD concentrations 
were ascertained in 5,870. Blood samples were not taken from those 
who had a clotting or bleeding disorder (eg, haemophilia or low 
platelets), had ever had a fit, were currently on anticoagulant drugs 
(eg, warfarin therapy) or were did not give their consent in writ-
ing. The analyses of blood samples were carried out at the Royal 
Victoria Infirmary (Newcastle-upon-Tyne, United Kingdom). Serum 
25OHD levels were measured by the Diasorin Liaison immunoassay 
that detects both 25OHD2 and 25OHD3 and therefore, provides 
the total circulating 25OHD level, as previously described (21). 
The assay for 25OHD has an analytical sensitivity (lower detection 
limit) of 7.5 nmol/L. The detection limit represents the lowest meas-
urable analyte level that can be distinguished from zero. All assays 
were performed in duplicate. The coefficient of variation ranged 
from 8.7% to 9.4%. The laboratory performing the 25OHD analy-
ses took part in the Internal and the Vitamin D External Quality 
Assessment Schemes (DEQAS).
Assessment of Depressive Symptoms
Depressive symptomatology was measured using the eight-item 
Center for Epidemiological Studies-Depression (CES-D) scale, a 
widely used self-report measure of depressive symptoms. CES-D is 
not a diagnostic instrument for clinical depression but can be used 
to identify people “at risk” of depression in population-based stud-
ies (24). This short version had good internal consistency at each 
wave (Cronbach’s α > .95) and comparable psychometric properties 
to the full 20-item CES-D (25,26). Five of the eight CES-D items 
(ie, felt depressed, was happy, felt lonely, enjoyed life, felt sad) were 
depressed mood items, while the remaining three (ie, everything was 
an effort, restless sleep, and could not get going) were somatic com-
plaints items (25). We derived a summary CES-D score by adding 
responses to all eight dichotomous questions (possible range: 0–8). 
To identify cases of elevated depressive symptoms that are possi-
ble cases of clinical depression we dichotomized the summary score 
around the cut point of four or greater (25,26). This definition has 
been validated against standardized psychiatric interviews in older 
populations (26).
Covariates
Total non-pension household wealth included financial wealth (sav-
ings and investments), the value of any home and other property (less 
mortgage), the value of any business assets and physical wealth such 
as artwork and jewellery, net of debt. Wealth is the most robust indi-
cator of socioeconomic circumstances in ELSA, and has been found 
to be more strongly associated with the risk of death than any other 
socioeconomic position indicator at older ages (27). The number 
of comorbidities, that is, cardiovascular disease and other chronic 
conditions was assessed by self-reported doctor diagnosed chronic 
diseases that included diabetes, cancer, stroke, arthritis, lung disease, 
and Parkinson’s and for cardiovascular diseases included high blood 
pressure, angina, heart attack, heart failure, heart murmur or heart 
rhythm. Smoking status was classified into nonsmokers, former 
smokers, or current smokers. Self-reported physical activity included 
questions about the frequency of participation in vigorous, moder-
ate, and mild physical activities; more than once per week, once per 
week, one to three times per month, hardly ever (sedentary). Physical 
activity was further categorized into four groups: sedentary; low; 
moderate and vigorous. Physical functioning was measured using 
self-reported limitations in the following basic Activities of Daily 
Living (ADL): dressing, walking across a room, bathing or shower-
ing, eating, getting in or out of bed, using the toilet. Self-reported 
limitations in the following Instrumental Activities of Daily Living 
(IADL): making telephone calls, shopping for groceries, preparing 
hot meal, doing work around the house or garden, taking medica-
tions, and managing money, such as paying bills and keeping track of 
expenses were also measured. A physical functioning limitation was 
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defined as having a limitation in one or more ADL or IADL activi-
ties. A total memory score was measured using a word-list learning 
test, in which 10 words were presented orally to study participants 
who were then asked to recall as many as possible immediately after 
reading them and then again after a 5-minute delay during which 
they completed other survey questions. We computed an overall 
memory score (range, 0–20) using both the immediate and delayed 
recall results (between-test correlation coefficient =  .70). Waist cir-
cumference was categorized into three main groups using sex-spe-
cific cut-offs: low (<94 cm for men and <80 cm for women), medium 
(≥94 cm and <102 cm for men; ≥80 cm and <88 cm for women) and 
high (≥102 cm for men and ≥88 cm for women).
Statistical Analyses
A complete case analysis with a final analytical sample of 5,607 par-
ticipants was performed. For stratified analyses by sex, there was a 
final analytical sample of 2,525 males, and 3,082 females. Whilst there 
was an absence of evidence of age or sex interactions with 25OHD 
quartiles, sex interactions were both apparent with other covariates 
used in the model and with 25OHD cut-offs. Logistic regression was 
used to investigate the unadjusted and adjusted association between 
25OHD levels with depressive symptoms. Due to the lack of inter-
national consensus (28), 25OHD levels, the independent variable, 
was categorized into quartiles: the lowest quartile (≤30  nmol/L), 
second quartile (30.01 until 46.00  nmol/L), third quartile (46.01 
until 64.00 nmol/L) and the highest quartile (>64.01 nmol/L; refer-
ence category). We have also categorized 25 OHD levels using the 
cut-off points recommended by the US Institute of Medicine (IOM) 
(29): <30  nmol/L; 30–50  nmol/L; >50  nmol/L. The UK National 
Osteoporosis Society (NOS 2013) recently proposed that IOM vita-
min thresholds should be adopted by UK practitioners. A truncated 
categorization of ≤50  nmol/L and >50  nmol/L was also used (6). 
Following the unadjusted model (model 1), a further five models 
(models 2 to 6) were derived to investigate the association between 
25OHD with depression, and adjusted for potential confounders. 
Each subsequent model included the variables that were included in 
the previous model. Model 2, adjusted for age, sex, and the season 
of the blood sampling. Model 3, further adjusted for wealth. Model 
4 further adjusted for health behaviors; smoking and physical activ-
ity. Model 5 further adjusted for health; number of cardiovascular 
conditions, number of non-cardiovascular chronic conditions, dif-
ficulties in ADL, difficulties in IADL and total memory score. Finally, 
model 6 further adjusted for waist circumference. The analyses were 
performed using STATA 13.0 (Stata Corp LLP, College Station, TX).
Ethics Approval and Informed Consent
All participants gave written informed consent. The National 
Research Ethics Service (London Multicentre Research Ethics 
Committee [MREC/01/2/91]) has approved the ELSA.
Results
Baseline characteristics of the sample for which 25OHD levels were 
ascertained by depression status and by gender can be found in the 
Supplementary Tables 1 and 2, respectively. Forty-two percent of 
the blood samples were taken in Autumn. Twelve percent reported 
depressive symptoms, and 61% and 56% reported cardiovascular 
and non-cardiovascular chronic conditions, respectively. The major-
ity did not report difficulties in performing either basic (85%) or 
instrumental (83%) ADL. 25OHD levels ranged between 9 and 
239 nmol/L and the mean was 48.70 nmol/L (SD = 23.57 nmol/L). 
The mean total memory score was 11 (SD = 3.5) and half of the par-
ticipants had a high waist circumference. Those for whom 25OHD 
data were not available compared with those for whom data were 
available were older and reported more ADL and IADL disability, 
more cardiovascular disease, depressive symptoms, sedentary life-
style, and lower level of wealth (p < .05 data not shown).
In the unadjusted analyses, low serum levels of 25OHD were 
associated with elevated depressive symptoms (Tables 1 and 2). 
The lowest and the second-lowest quartiles of 25OHD (odds ratio 
[OR] = 2.40, 95% confidence interval [CI] = 1.89–3.04; OR = 1.58, 
95% CI  =  1.23–2.03; Table  1, model 1)  as well as 25OHD lev-
els <30 nmol/L, 30–50 nmol/L and ≤50 nmol/L (OR = 2.26, 95% 
CI  =  1.85–2.76; OR=1.35, 95% CI  =  1.10–1.64; OR=1.71, 95% 
CI = 1.44–2.03; Table 2, model 1) were significantly associated with 
higher levels of depressive symptoms in the unadjusted analysis. This 
association remained statistically significant even after the adjust-
ment for all covariates included in the models but with attenuation 
in the OR from model 2 to model 6 (Tables 1 and 2). For women, 
those in the lowest (OR = 2.17, 95% CI = 1.60–2.93) and second 
lowest (OR = 1.69, 95% CI = 1.23–2.32) quartiles of 25OHD as 
well as those with 25OHD levels <30  nmol/L (OR  =  1.92, 95% 
CI = 1.50–2.47), 30–50 nmol/L (OR = 1.38, 95% CI = 1.07–1.77) 
and ≤50 nmol/L (OR = 1.61, 95% CI = 1.30–2.00) were more likely 
to report elevated depressive symptoms. This association remained 
statistically significant even after adjustment for all covariates 
included in the models but with less marked decline in OR from 
model 2 to model 6 (Table 1 and 2). For men, however, the only 
association that remained significant in the fully adjusted model 
was for those with 25OHD levels <30  nmol/L (OR  =  1.60, 95% 
CI = 1.06–2.42; Table 2, model 6).
Discussion
In this large population-based cohort of older adults aged 50 years 
and older, we demonstrated that older English adults from the gen-
eral population who have low 25OHD serum levels are more likely 
to report elevated depressive symptoms. This study observed sig-
nificant negative associations between 25OHD levels and elevated 
depressive symptoms especially among women. In our analyses, 
the association observed between low 25OHD levels and elevated 
depressive symptoms was independent of confounders: age, eco-
nomic circumstances and a wide range of health conditions, health 
behaviors, physical function, and cognitive function.
Observational studies provide some evidence for a relationship 
between vitamin D deficiency and depression (20,30–35). Findings 
from the present study are consistent with other studies (20) in which 
increased elevated depressive symptoms were seen in individuals 
with low vitamin D status. Various reviews suggested an association 
between vitamin D and depression (30–35), and recent systematic 
review and meta-analysis of observational studies and randomized 
controlled trials concluded that low vitamin D concentration is asso-
ciated with depression in adults (15,18–20).
Low vitamin D levels have been observationally associated with 
depression and depressive symptoms and, therefore, an antidepressant 
effect of vitamin D supplementation could be expected. The potential 
role for vitamin D in late-life depression prevention and treatment 
remains uncertain. A  systematic review aimed to summarize the evi-
dence of randomized clinical trials to assess the efficacy of oral vita-
min D supplementation in depression compared with placebo (21) 
concluded that there was insufficient evidence to support the efficacy 
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Table 2. Multivariable Logistic Regression Analyses Investigating the Association Between Depression and 25-Hydroxy Vitamin D (25OHD) 
by Classification System
Model 1 (unadjusted) Model 2 Model 3 Model 4 Model 5 Model 6
25OHD OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
IOM cut points (29)
 All participantsa
  >50 nmol/L 1 1 1 1 1 1
  30–50 nmol/L 1.35 (1.10–1.64) 1.36 (1.11–1.67) 1.24 (1.01–1.53) 1.23 (1.00–1.52) 1.24 (1.00–1.54) 1.26 (1.01–1.56)
  <30 nmol/L 2.26 (1.85–2.76) 2.25 (1.82–2.77) 1.72 (1.39–2.14) 1.55 (1.24–1.93) 1.43 (1.14–1.80) 1.45 (1.15–1.83)
 Males
  >50 nmol/L 1 1 1 1 1 1
  30–50 nmol/L 1.31 (0.93–1.85) 1.37 (0.96–1.94) 1.22 (0.85–1.74) 1.11 (0.78–1.60) 1.20 (0.82–1.76) 1.18 (0.80–1.73)
  <30 nmol/L 2.87 (2.06–4.00) 3.09 (2.15–4.45) 2.14 (1.47–3.11) 1.76 (1.19–2.59) 1.63 (1.08–2.46) 1.60 (1.06–2.42)
 Females
  >50 nmol/L 1 1 1 1 1 1
  30–50nmol/L 1.38 (1.07–1.77) 1.37 (1.06–1.76) 1.25 (0.97–1.62) 1.29 (1.00–1.67) 1.27 (0.97–1.65) 1.32 (1.01–1.72)
  <30 nmol/L 1.92 (1.50–2.47) 1.90 (1.47–2.47) 1.53 (1.17–2.00) 1.44 (1.10–1.89) 1.34 (1.01–1.77) 1.40 (1.06–1.86)
Truncated cut points
 All participantsa
  >50 nmol/L 1 1 1 1 1 1
  ≤50 nmol/L 1.71 (1.44–2.03) 1.69 (1.41–2.02) 1.43 (1.19–1.71) 1.36 (1.13–1.64) 1.32 (1.09–1.60) 1.34 (1.10–1.62)
 Males
  >50 nmol/L 1 1 1 1 1 1
  ≤50 nmol/L 1.88 (1.40–2.52) 1.89 (1.39–2.57) 1.53 (1.12–2.10) 1.34 (0.97–1.85) 1.36 (0.97–1.92) 1.34 (0.95–1.88)
 Females
  >50 nmol/L 1 1 1 1 1 1
  ≤50 nmol/L 1.61 (1.30–2.00) 1.58 (1.27–1.97) 1.37 (1.09–1.71) 1.35 (1.08–1.70) 1.30 (1.03–1.64) 1.35 (1.07–1.72)
Notes: CI = confidence interval; IOM = Institute of Medicine; OR = odds ratio. Model 1: 25OHD (unadjusted); Model 2: Model 1 + adjusted for sexa, age group, 
and season; Model 3: Model 2 + adjusted for wealth; Model 4: Model 3 + adjusted for smoking, and physical exercise; Model 5: Model 4 + adjusted for number 
of cardiovascular conditions, number of non-cardiovascular conditions, difficulties in activities of daily living, difficulties in instrumental activities of daily living, 
and total memory score; Model 6: Model 5 + adjusted for waist circumference.
aModels 2 to 6 also adjusted for sex.
Table 1. Multivariable Logistic Regression Analyses Investigating the Association Between Depression and 25-Hydroxy Vitamin D (25OHD) 
Concentrations
Model 1 (unadjusted) Model 2 Model 3 Model 4 Model 5 Model 6
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
All participantsa
25OHD
 Highest quartile 1 1 1 1 1 1
 3rd quartile 1.16 (0.89–1.52) 1.18 (0.90–1.53) 1.12 (0.86–1.47) 1.15 (0.88–1.51) 1.19 (0.90–1.57) 1.20 (0.91–1.59)
 2nd quartile 1.58 (1.23–2.03) 1.60 (1.24–2.06) 1.41 (1.09–1.83) 1.44 (1.11–1.87) 1.46 (1.12–1.91) 1.49 (1.13–1.95)
 Lowest quartile 2.40 (1.89–3.04) 2.39 (1.87–3.07) 1.80 (1.39–2.32) 1.65 (1.27–2.14) 1.55 (1.18–2.02) 1.58 (1.20–2.07)
Males
25OHD
 Highest quartile 1 1 1 1 1 1
 3rd quartile 1.03 (0.66–1.61) 1.01 (0.64–1.59) 0.93 (0.59–1.47) 0.92 (0.58–1.46) 0.95 (0.59–1.55) 0.94 (0.58–1.53)
 2nd quartile 1.42 (0.93–2.18) 1.46 (0.95–2.25) 1.24 (0.80–1.92) 1.16 (0.74–1.81) 1.24 (0.77–1.98) 1.21 (0.75–1.94)
 Lowest quartile 2.75 (1.85–4.08) 2.91 (1.90–4.44) 1.92 (1.24–2.98) 1.61 (1.03–2.51) 1.47 (0.92–2.36) 1.44 (0.90–2.31)
Females
25OHD
 Highest quartile 1 1 1 1 1 1
 3rd quartile 1.26 (0.91–1.75) 1.27 (0.92–1.77) 1.22 (0.88–1.71) 1.29 (0.92–1.81) 1.32 (0.94–1.86) 1.38 (0.98–1.95)
 2nd quartile 1.69 (1.23–2.32) 1.69 (1.23–2.32) 1.52 (1.10–2.09) 1.60 (1.15–2.12) 1.58 (1.13–2.19) 1.68 (1.20–2.35)
 Lowest quartile 2.17 (1.60–2.93) 2.16 (1.58–2.94) 1.72 (1.25–2.36) 1.66 (1.20–2.28) 1.57 (1.13–2.18) 1.67 (1.20–2.34)
Notes: CI = confidence interval; OR = odds ratio. Model 1: 25OHD (unadjusted); Model 2: Model 1 + adjusted for sexa, age group, and season; Model 3: Model 
2 + adjusted for wealth; Model 4: Model 3 + adjusted for smoking, and physical exercise; Model 5: Model 4 + adjusted for number of cardiovascular conditions, 
number of non-cardiovascular conditions, difficulties in activities of daily living, difficulties in instrumental activities of daily living, and total memory score; Model 
6: Model 5 + adjusted for waist circumference.
aModels 2 to 6 also adjusted for sex.
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of vitamin D supplementation in depression symptoms, and more 
randomized clinical trials using depressed patients are warranted. In 
contrast, Shaffer et al found that vitamin D supplementation may be 
effective for reducing depressive symptoms in patients with clinically 
significant depression; however, further high quality research is needed 
(19). Similarly, a systematic review and meta-analysis comparing studies 
with and without biological flaws concluded that vitamin D supple-
mentation was somewhat favorable in the management of depression 
in studies that demonstrate a change in vitamin levels, and the effect size 
was comparable to that of antidepressant medication (15,18).
It is difficult to identify the causal relation given the observa-
tional design of most studies investigating the link between vitamin 
D and depression and the numerous potential confounders, espe-
cially when there is reverse causality between serum vitamin level 
and depression. For example, depressed individuals tend to go out-
side less frequently and thus are typically less exposed to sunlight. In 
addition, their associated reduced appetite may also lead to dietary 
changes that then reduce their vitamin D levels.
Although the association between vitamin D and depression has 
not yet been confirmed, there are indications that a low vitamin D 
concentration may predispose to depression through several biologi-
cal mechanisms. Current hypotheses about the pathophysiological 
mechanisms in the association between vitamin D and depression 
include a role for vitamin D in the regulation of the neurotransmit-
ters dopamine, noradrenaline and acetylcholine, as well as an effect 
on neurotrophic factors (36). Moreover, vitamin D receptors are 
found in the prefrontal cortex and parts of the limbic system. These 
brain areas have been implicated in the pathophysiology of depres-
sion (36). Vitamin D may also indirectly fight depressive symptoms 
via its proposed anti-inflammatory effect (37). Another important 
function of vitamin D is to control the formation of serotonin and 
this is another feature of the link between vitamin D deficiency and 
depression (38). It has been shown that one of the actions of vita-
min D is to induce the expression of the serotonin-synthesizing gene 
tryptophan hydroxylase 2 while repressing the expression of trypto-
phan hydroxylase 1. Both tryptophan hydroxylase 1 and tryptophan 
hydroxylase 2 play a role in serotonin synthesis. Vitamin D may thus 
prevent depression by maintaining normal serotonin levels.
Our findings showed that amongst women there was an elevated 
risk for depression over a broader range of vitamin D deficiency of less 
or equal to 50 nmol/L and in the lowest two quartiles of 25OHD in 
women. For men, however, an elevated risk for depression was true 
only for a deficiency of lower than 30 nmol/L. A higher prevalence of 
depression in women compared with men is consistent across nations, 
cultures, and population groups, in studies using different methods and 
measurement instruments, and for a diversity of incidence and preva-
lence indicators (39). Cross-national comparative research and meta-
analyses usually put the gender ratio in the prevalence of depression in 
Western countries at approximately 2:1 (40). In addition, a higher prev-
alence of vitamin D deficiency in women has also been reported (16).
Given the high prevalence of both vitamin D deficiency and 
depression, an association between these two conditions would have 
significant public health implications, particularly as supplementa-
tion with vitamin D is cost-effective and without significant adverse 
effects. The increase of the natural production of serotonin by vita-
min D could potentially enhance serotonin that is taken orally as 
an antidepressant. The clinical implications of our findings are that 
health professionals should be alerted to complaints presented to 
them by older people, so that appropriate interventions can be pro-
vided, as vitamin D deficiency and late-life depression are common 
in older people and both have adverse health consequences.
Our study has several strengths and potential limitations that need 
to be considered. As one of the largest samples with vitamin D levels in 
the United Kingdom, a major strength is the large and representative 
sample of community-dwelling English men and women aged 50 years 
and older using a wide range of covariates. In addition, certified exam-
iners following standardized protocols, assuring excellent quality of 
data, performed all examinations and laboratory measurements. We 
have also used an internationally validated questionnaire specific for 
depressive symptoms. Limitations arise from the cross-sectional study 
design, which investigates associations but cannot provide evidence of 
causality. Data on repeated measures for vitamin D were not available, 
and therefore we could not investigate the directionality of the associa-
tion, and whether depressive symptoms occurred after vitamin D defi-
ciency. However, ELSA is planning to measure levels of vitamin D again 
in its eighth wave (2016–2017), which will enable longitudinal analyses 
utilizing these repeated measures. We were unable to assess differences 
between vitamin D2 and vitamin D3 as the respective data were not 
available in ELSA. Another potential limitation could be attributed to 
selection bias, in that out of the 9,169 participants eligible for a nurse 
visit at which blood samples could be taken, 25OHD concentrations 
were ascertained in 5,870. However, it is also possible that our effect 
estimates may be conservative since people who gave blood were more 
likely to be healthier than those who did not. Lack of knowledge of 
current antidepressant use could create a bias, although this seems 
unlikely to have had a substantial effect since only 3% of our popula-
tion reported having used antidepressants in the last 2 years. Our find-
ings were obtained in community-dwelling subjects mainly aged below 
80 years, with low disability and might not be representative of frailer, 
or older subjects, and nursing home residents. Finally, reverse causal-
ity, in which depression leads to decreased sun exposure and poorer 
dietary intake, thereby causing vitamin D deficiency, cannot be ruled out 
in cross-sectional studies.
In summary, our study suggests a potential role of 25OHD in 
depression, especially among women. Our findings, therefore, con-
tribute significantly to the body of evidence supporting a role for 
vitamin D in depression. Whether our findings have any clinical 
meaning or not, additional data from well-designed randomized 
controlled trials of vitamin D for the prevention and treatment of 
depression in late-life are needed. The development of strategies to 
prevent late-life depression is necessary to reduce its impact on dis-
ease burden and associated costs.
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